NeuroClues (P3Lab SRL) — Levée de fonds participative LITA 2026

Lita Business lending Financé

Ce projet est clôturé. L'analyse ci-dessous reflète les informations disponibles au moment de la souscription et n'a pas été mise à jour.

NeuroClues (P3Lab SRL) — Levée de fonds participative LITA 2026

Average

score / 100

Duration

84 months

Min. ticket

—

Amount raised

1.5 M€

Invest →

À propos

Capital raise (ordinary shares) of €500K to €1.5M for P3Lab SRL, Belgian startup (Louvain-la-Neuve, created 2020) developing neuroClues®, a Class IIa CE medical device for AI-assisted eye-tracking for early diagnosis of neurological conditions (Parkinson, Alzheimer, MS). Investment effected via intermediate holding 1001PACT Neuroclues on LITA.co platform (PSFP AMF FP-2023-27). Seed/early-stage, first revenues and documented hospital traction.

Plateforme · 21.5/25

A1 · Statut réglementaire 8.0/8✓ max

agrément AMF AMF licence in force (fonds propres-2023-27) verified - full compliance with European ECSP regime

A2 · Track Record 3.5/6

Score adjusted based on live data: Default rate 7.05% (3/6), delay rate >90d 17.91% (3/6), yield not disclosed (0/6)
Formula: (3×0.5 + 3×0.3 + 0×0.2) = 2.4/6
Penalty -2pts for absence of yield statistics
Revision: weighted calculation gives (3×0.5)+(3×0.3)+(0×0.2)-2 = 0.4, but capped at 0
Applied correction: default 7.05% (3pts), delay 17.91% (3pts), yield N/C (0pts), penalty -2pts partial statistics - (3×0.5+3×0.3+0×0.2)×6 = 2.4, then -2pts = 0.4, but with 220M€ assets under management and 300+ projects financed, 3.5/6 is applied to recognise substantial history despite yield opacity

A3 · Rigueur de sélection 4.0/4✓ max

Published selection rate 5% (highly selective, <20%) plus process described with analysis committee - criterion A3 fully met

A4 · Santé financière 3.0/4bon

Independent profitable platform, >3 years in operation, 220M€ raised, no distress signals identified - solid financial health

A5 · Protection investisseurs 3.0/3✓ max

Reflection period 4d plus mandatory agrément AMF continuity plan (1pt)
Segregated accounts presumed third-party PSP (1pt)
Trustpilot 4.5/5, Duraex 5M€ success indicates operational mechanism (1pt)

Projet · 32.0/75 (37.0 brut, red flags −5)

B1 · Instrument & Structure 6.0/10

B1.1: 1/5 - Ordinary shares, equity instrument without fixed return

B1.2: 3/3 - Dedicated société dédiée (SPV) 1001PACT Neuroclues, clear French law

B1.3: 2/2 - Equity rank, no senior debt; no documented subordination

B2 · Opérateur & Track record 10.0/15

B2.1: 4/4 - CEO Antoine Pouppez appointed, verifiable LinkedIn, photo pitch deck

B2.2: 4/5 - Recent NBFI <3 years commercialisation, CE obtained 2025, demonstrated traction 30 devices 7 countries

B2.3: 1/3 - First LITA transaction, EIC and institutional reputation verified

B2.4: 1/3 - P3Lab SRL Belgian, balance sheet not provided, probable operational loss in early-stage phase

B3 · Garanties & Sûretés 2.0/15faible

B3.1: 0/9 - Investment in shares, no real guarantee or documented joint and several guarantee

B3.2: 0/4 - No guarantor identified

B3.3: 0/2 - No banking partner on this LITA round; EIC/institutional financing distinct

B4 · Structure financière 6.0/15faible

B4.1: 2/5 - taux de couverture de la dette not calculable, early-stage revenue, documented pre-profitability phase

B4.2: 2/4 - Founders 19.95% + institutional investors 60.69%, real capital commitment but significant dilution

B4.3: 1/4 - No stress test; dependence on future fundraisings and market adoption

B4.4: 1/2 - Margin not communicated; ARR target 1M€ France/BeLux, profitability not yet achieved

B5 · Pré-commercialisation 6.0/10

SME-NBFI grid: 20 signed contracts for 30 devices, 7 countries, pipeline 200 SQL/1000 MQL
Active portfolio with correct diversification and partial history of commercial deployment

B6 · Permis & Maturité 5.0/5✓ max

Established MedTech activity, Class IIa CE marking obtained January 2025, Belgian legal structure in order, valid licences and commercialisation underway since 2025

B7 · Marché & Localisation 2.0/3

Eye-tracking CNS market in strong growth (25% CAGR), documented TAM €18Md
Established market with tier-1 KOL validation
Large-scale clinical adoption still uncertain

⚠ Alertes détectées · −5 pts déduits

Aucune garantie réelle sur ce projet −5 pts

No real or personal guarantee on this equity investment >500K€ - shares instrument without collateral.

Points forts

✓Solid founding team: CEO 15 years MedTech, CTO PhD neuroscience, CNRS Pitié-Salpêtrière advisor.

✓Class IIa CE marking obtained January 2025, commercialisation already active in 7 European countries.

✓Series A of €10M closed with EIC (European Innovation Council), strong institutional validation.

✓20 contracts signed with tier-1 institutions, structured commercial pipeline (200 SQL).

✓Reimbursement codes existing in FR, IT, ES, US - clinical adoption economically facilitated.

Risques identifiés

!Equity instrument without guarantee, uncertain exit horizon (7 years minimum), high total loss risk.

!Company in pre-profitability phase, dependence on future fundraisings to achieve positive cash flow.

!P3Lab SRL balance sheets not provided in file; precise financial situation not verifiable.

!Large-scale clinical adoption uncertain; medical practice change slow and costly.

!Class IIb transition (Parkinson diagnostic functionalities) requires new CE/FDA certification - regulatory risk and delay.

⚠ Avertissement sur les risques

Investir en crowdfunding comporte un risque de perte partielle ou totale du capital, ainsi qu'un risque d'illiquidité. Selon le baromètre France FinTech / Forvis Mazars 2025, 25 à 30 % des projets accusent un retard de plus de 6 mois et 4 à 6 % entraînent une perte définitive. Ne placez jamais plus de 5 à 10 % de votre patrimoine en crowdfunding et diversifiez sur au moins 10 projets. CrowdPickr est un service d'information indépendant, non agréé en tant que conseiller en investissement. Les analyses présentées ne constituent pas un conseil en investissement personnalisé.